Rxo (RXO) Asset Writedowns and Impairment (2024 - 2026)

Rxo has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment changed 0.0% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $22.0 million (changed N/A YoY), and the FY2025 full-year result was $4.0 million, down 69.23% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $4.0 million, up from $1.0 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $13.0 million in Q4 2024, with the low at $1.0 million in Q4 2025.
• Historically, Asset Writedowns and Impairment has averaged $5.5 million across 3 years, with a median of $4.0 million in 2025.
• Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment tumbled 92.31% — and 2026, when it changed 0.0%.
• Rxo's Asset Writedowns and Impairment stood at $13.0 million in 2024, then plunged by 92.31% to $1.0 million in 2025, then jumped by 300.0% to $4.0 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $4.0 million (Q1 2026), $1.0 million (Q4 2025), and $4.0 million (Q1 2025), per Business Quant data.